Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,573
  • Shares Outstanding, K 63,807
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,190 K
  • EBIT $ -28 M
  • EBITDA $ -24 M
  • 60-Month Beta 0.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.90
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.58
  • Most Recent Earnings $-0.14 on 08/14/24
  • Next Earnings Date 12/27/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 259.43% ( +34.56%)
  • Historical Volatility 150.78%
  • IV Percentile 88%
  • IV Rank 31.25%
  • IV High 808.15% on 11/18/24
  • IV Low 10.05% on 08/14/24
  • Put/Call Vol Ratio 0.90
  • Today's Volume 462
  • Volume Avg (30-Day) 238
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 13,689
  • Open Int (30-Day) 11,601

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4947 +47.54%
on 12/06/24
1.0900 -33.04%
on 12/19/24
+0.1019 (+16.23%)
since 11/20/24
3-Month
0.4947 +47.54%
on 12/06/24
1.1300 -35.41%
on 10/02/24
-0.3501 (-32.42%)
since 09/20/24
52-Week
0.4947 +47.54%
on 12/06/24
3.2300 -77.40%
on 12/27/23
-1.9901 (-73.17%)
since 12/20/23

Most Recent Stories

More News
Have a Relaxing Holiday Season

Monday U.S. Economic Lookahead Consumer confidence (Dec.) Featured Earnings Limoneira ...

OTLK : 1.4400 (+3.60%)
PFX : 49.70 (+0.61%)
LMNR : 26.30 (+2.49%)
CVM : 0.7299 (-4.60%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.8310 (-6.36%)
PYXS : 1.6900 (+9.74%)
RPTX : 1.3200 (unch)
IMRX : 2.00 (+8.70%)
CVM : 0.7299 (-4.60%)
ONC.TO : 1.19 (-9.16%)
Goodbye ’23

Monday U.S. and Canada Christmas Day, Markets Closed Tuesday U.S. Economic ...

CVM : 0.7299 (-4.60%)
CTXR : 2.60 (+1.17%)
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments

EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END

TCBP : 0.6600 (+0.15%)
CVM : 0.7299 (-4.60%)
INVO : 0.8330 (-2.91%)
SNY : 47.71 (+0.44%)
PFE : 26.36 (+2.29%)
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public...

CVM : 0.7299 (-4.60%)
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Corporation (NYSE American: CVM) today announced it has held a productive pre-submission meeting with Canada’s regulator to determine the best regulatory path toward market approval. Based...

CVM : 0.7299 (-4.60%)
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension

CEL-SCI Corporation (NYSE American: CVM) today reported new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma of the head...

CVM : 0.7299 (-4.60%)
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology

CEL-SCI Corporation (NYSE American: CVM) today announced it will present new data from its pivotal Phase 3 study, the largest study ever conducted in newly diagnosed locally advanced squamous cell carcinoma...

CVM : 0.7299 (-4.60%)
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments.

CVM : 0.7299 (-4.60%)
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments

CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2022, as well as key clinical and corporate developments.

CVM : 0.7299 (-4.60%)

Business Summary

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins,...

See More

Key Turning Points

3rd Resistance Point 0.8446
2nd Resistance Point 0.7917
1st Resistance Point 0.7608
Last Price 0.7299
1st Support Level 0.6770
2nd Support Level 0.6241
3rd Support Level 0.5932

See More

52-Week High 3.2300
Fibonacci 61.8% 2.1851
Fibonacci 50% 1.8623
Fibonacci 38.2% 1.5396
Last Price 0.7299
52-Week Low 0.4947

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar